M&A Deal Summary

Montreux Equity Partners and MPE Partners Acquire OREXIGEN Therapeutics

On November 22, 2006, growth capital firm Montreux Equity Partners and private equity firm MPE Partners acquired life science company OREXIGEN Therapeutics for 30M USD

Acquisition Highlights
  • This is Montreux Equity Partners’ 4th and MPE Partners’ 4th transaction in the Life Science sector.
  • This is Montreux Equity Partners’ and MPE Partners’ largest (disclosed) transaction.
  • This is Montreux Equity Partners’ 11th and MPE Partners’ 36th transaction in the United States.
  • This is Montreux Equity Partners’ 11th and MPE Partners’ 16th transaction in California.
Investment Fate
  • OREXIGEN Therapeutics went public in 2007.
  • OREXIGEN Therapeutics was sold to a strategic buyer in 2018 for 75M USD.

M&A Deal Summary

Date 2006-11-22
Target OREXIGEN Therapeutics
Sector Life Science
Buyer(s) Montreux Equity Partners
MPE Partners
Deal Type Buyout (LBO, MBO, MBI)
Deal Value 30M USD

Target

OREXIGEN Therapeutics

La Jolla, California, United States
website
Orexigen Therapeutics, Inc. is a bio-pharmaceutical company focuses on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA.

Search 190,634 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 2

DESCRIPTION

Montreux Equity Partners is a growth investment firm focused on investing in commercial stage companies with category leading products, technologies, and services. Montreux Equity Partners looks to invest $10 to $20 million in fast growing companies with $5 to $50 million in revenue. Montreux Equity Partners was formed in 1993 and is headquartered in San Francisco, California.


DEAL STATS #
Overall 11 of 27
Sector (Life Science) 4 of 8
Type (Buyout (LBO, MBO, MBI)) 1 of 3
State (California) 11 of 20
Country (United States) 11 of 25
Year (2006) 2 of 2
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2006-01-01 Avantis Medical Systems

San Jose, California, United States

Avantis Medical Systems, Inc. develops and manufactures catheter-based endoscopic devices. Its initial focus is on devices for use in both detecting and treating cancers of the gastrointestinal (GI) tract. Avantis Medical Systems was founded in 2004 and is based in San Jose, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2007-01-01 Cerexa

Oakland, California, United States

Cerexa, Inc. was a privately held specialty pharmaceutical company, created as a spin-out from the sale of Peninsula Pharmaceuticals to Johnson & Johnson, focused on developing and commercializing novel anti-infective therapies for the treatment of life-threatening infections.

Sell $480M
Buyer

MPE Partners

Cleveland, Ohio, United States

Investor Investor Investor Investor Investor

website


Category Private Equity Firm
Founded 1968
PE ASSETS 3.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

MPE Partners is a Midwest based investment firm principally focused private equity investments throughout North America. MPE has a preference for buyouts and recapitalizations of lower middle-market, family and entrepreneur owned businesses. The Firm looks for stand-alone companies operating in the 'high-value' manufacturing or business services sectors. MPE seeks businesses with at least $5 million of EBITDA and valued up to $250 million. MPE Partners is headquartered in Cleveland, Ohio.


DEAL STATS #
Overall 38 of 83
Sector (Life Science) 4 of 13
Type (Buyout (LBO, MBO, MBI)) 4 of 9
State (California) 16 of 25
Country (United States) 36 of 79
Year (2006) 6 of 6
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2006-11-10 Solta Medical

Hayward, California, United States

Solta Medical, Inc. is a designer, developer, manufacturer and marketer of medical devices for the non-invasive treatment of wrinkles.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2007-02-13 Trellis Bioscience

South San Francisco, California, United States

Trellis Bioscience is a biotechnology company that developed a breakthrough technology platform for discovery and selection of very rare cells that produce ideal proteins such as antibodies, selected for specificity, selectivity, affinity, secretion rate and other desired characteristics.

Buy -